Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01446055
Other study ID # TGResQ082011
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received September 23, 2011
Last updated October 8, 2011
Start date October 2011
Est. completion date April 2013

Study information

Verified date October 2011
Source Xuanwu Hospital, Beijing
Contact Yongquan Gu, MD
Phone 13910002909
Email gu-yq@263.net
Is FDA regulated No
Health authority China: Ministry of Health
Study type Interventional

Clinical Trial Summary

Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective. However, processing bone marrow by Ficoll density gradient centrifugation is not only time consuming but also expensive. Manually processing of bone marrow also results in large variation in therapeutic cell quantity and quality which directly leads deviation of safety and efficacy of the cell therapy. This study is aiming to compare an automated bone marrow processing system with a conventional manual method in term of safety and efficacy.


Description:

Using autologous bone marrow mononuclear cells (BM-MNC) to treat patients with chronic limb ischemia has been proved safe and effective. However, processing bone marrow by Ficoll density gradient centrifugation is not only time consuming but also expensive. Manually processing of bone marrow also results in large variation in therapeutic cell quantity and quality which directly lead deviation of safety and efficacy of the cell therapy. This study is aiming to compare an automated bone marrow processing system with a conventional manual method in term of safety and efficacy.

ResQ system developed by Thermogenesis in USA provides an automatic cell processing system for bone marrow. The system takes less than 30 minutes to concentrate the therapeutic mononuclear cells including stem cells in a closed system without adding any additive such as separation reagent (Ficoll). The system also be able to be operated at point of care.

The study is designed to prove no inferior of safety and efficacy of bone marrow cells processed by ResQ to those of cells using conventional manual method. The conventional manual method is involved Ficoll density gradient centrifugation and cell washing stems in an open system. Each of test arms (ResQ vs manual method) consists of 25 patients. The primary outcome is safety which is measured by cell treatment-related adverse events. The secondary endpoints include resting ankle-brachial pressure index (ABI)and toe brachial pressure index (TBI) , transcutaneous oxygen pressure (TcPO2), claudication distance, rest pain scale evaluation, collateral vessel scale, etc.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date April 2013
Est. primary completion date April 2012
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

1. fontaine's stage 2-4 or resting ABI <0.7

2. age between 20 and 80 years old

3. sign informed consent, voluntary subjects

4. diagnosis of lower extremity arterial occlusive disease, or diabetic lower limb ischemia, or Buerger's disease

Exclusion Criteria:

1. poorly controlled diabetes (HBA1c> 7.0%) and proliferative retinopathy (III-IV stage)

2. malignancy history in the past five years or serum level of tumor markers elevated more than doubled

3. severe heart, liver, kidney, respiratory failure or poor general condition can not tolerate BM-MNC transplantation

4. serious infections (such as cellulitis, osteomyelitis, etc.)or gangrene that a major amputation cannot be avoided

5. aortic or iliac or common femoral artery occlusion

6. pregnant female, or reproductive age female who wants to give birth throughout the course of the study

7. life expectancy less than a year

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Intervention

Device:
ResQ processed bone marrow sample
Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
Ficoll conventional cell processing method
Comparison of different cell processing methods

Locations

Country Name City State
China Xuan Wu Hospital Beijing Beijing

Sponsors (3)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing Hebei Medical University, Thermogenesis Corp.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cell treatment-related adverse event Temperature,Pulse,Respiration,Blood Pressure
Routine analysis of blood and urine,
Liver function(ALT:alanine aminotransferase,AST:aspartate transferase), Renal function(Blood urea nitrogen,Creatinine;) Function of coagulation(APTT,PT,Fib,TT)
ECG(Electrocardiography)
local inflammatory response
Cell-treatment related death
Cell-treatment related unexpected amputation.
2-wk after bone marrow transplantation Yes
Secondary ulcer size Measuring ulcer area (cm2) and depth (mm)of limb :
For each ulcer , photographically record the area and depth with a ruler in order to calculate the ulcer area in square millimeters.
Post bone marrow transplantation: 1, 3, 6, 12 months No
Secondary rest pain score. Scoring the rest pain based on the degree of pain as following five scales):
0 level-0 point: no pain;
level-1 point: occasional pain which can be recalled;
level-2 points: the pain often but can be tolerated, without or with a little analgesics;
level-3 points: often with need of general analgesics;
level -4 points: affect sleeping due to the pain, general pain medication being difficult to alleviate.
Before transplantation: points; after transplantation: points.
Post bone marrow transplantation: 1,3, 6, 12 months No
Secondary cold sensation score based on a sense of cold as following five scales: 0 level-0 point: no cold sensation;
level-1 point, or : Accasionally cold feeling;
level-2 points: Often with cold feeling;
level-3 points: significantly cold feeling. and can be significantly improved when using a local insulation.
level-4 points: significantly cold feeling,and can not be significantly improved when using a local insulation.
Post bone marrow transplantation:,1,3, 6, 12 months No
Secondary claudication distance (m) Measurement of claudication distance (m): For patients with intermittent claudication, treadmill exercise test (no tilt, speed 3km/hr) is employed to measure claudication distance. Post bone marrow transplantation:1, 3, 6, 12 months No
Secondary Resting ABI Measurement of ABI(ankle brachial index, ABI):
Measure arterial pressure with a laser Doppler, and then calculate the ankle-brachial index, that is a ratio of ankle arterial blood pressure to brachial arterial blood pressure at rest.
Post bone marrow transplantation: 1,3, 6, 12 months No
Secondary Resting TcPO2 (mmHg) Transcutaneous oxygen pressure(TcPO2) should be measured at the same site in the ischemic limb at rest. Post bone marrow transplantation:1, 3, 6, 12 months No
Secondary Collateral vessel score Collateral vessel score:
Using DSA(Digital subtraction angiography)or CTA(computed tomographic angiography) to score the collateral vessel formation.
A mean score is obtained for each ischemic limb by 3 independent interventionists based on the following 4 level score:
0 (no new collateral vessels)
1 (A little new collateral vessels)
2 (moderate new collateral blood vessels)
3 (Rich new collateral vessels)
Post bone marrow transplantation: 1,3, 6, 12 months No
Secondary Amputation rate Amputation rate and level is recorded. Post bone marrow transplantation:1, 3, 6, 12 months No
Secondary Skin microcirculation measurement using PeriMed "laser-Doppler flowmetry" measure the skin microcirculation on the same site in the ischemic limb at rest. 1,3,6,12 months post transplantation No
Secondary Resting TBI Measurement of TBI(Toe Brachial Index):
Measure arterial pressure with a laser Doppler, and then calculate Toe Brachial Index, that is a ratio of toe arterial blood pressure to brachial arterial blood pressure.
Post bone marrow transplantation: 1,3, 6, 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A